Crigler Najjar Syndrome News and Research

RSS
Preliminary results of AAV-mediated gene therapy for Crigler Najjar syndrome

Preliminary results of AAV-mediated gene therapy for Crigler Najjar syndrome

Landmark 30-year study describes clinical course of patients with Crigler-Najjar syndrome

Landmark 30-year study describes clinical course of patients with Crigler-Najjar syndrome

Researchers are developing and testing novel gene therapy to cure Crigler-Najjar syndrome

Researchers are developing and testing novel gene therapy to cure Crigler-Najjar syndrome

Regenerative medicine scientist receives $1.3 million to study stem cell therapy for liver failure

Regenerative medicine scientist receives $1.3 million to study stem cell therapy for liver failure

Collaborative effort to develop rare disease patient registries

Collaborative effort to develop rare disease patient registries

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.